April 10, 2008
RXi's ALS Research Published
Findings by RXi Pharmaceuticals Corp. of Worcester on a treatment for Lou Gehrig's Disease have been published in the April edition of a peer-reviewed science journal.
The Journal of Biological Chemistry selected the paper as a "paper of the week," meaning it ranks in significance in the top 1 percent of papers they review.
The research, performed by UMass Medical School researchers and RXi scientific advisors, used animal models to demonstrate the use of RNA interference to inhibit a gene that can cause ALS.
In January, RXi announced that it had entered into an exclusive licensing agreement with the medical school for the technology described in the paper.
The Journal of Biological Chemistry selected the paper as a "paper of the week," meaning it ranks in significance in the top 1 percent of papers they review.
The research, performed by UMass Medical School researchers and RXi scientific advisors, used animal models to demonstrate the use of RNA interference to inhibit a gene that can cause ALS.
In January, RXi announced that it had entered into an exclusive licensing agreement with the medical school for the technology described in the paper.
WBJ Web Partners
Most Recent
Most Recent
0 Comments